. 2012 Oct 8;6(2):e18. doi: 10.4081/oncol.2012.e18

Table 3. Adjuvant chemotherapy and chemoimmunotherapy trials in renal cell cancer.

Author	No. patients	Stage	Treatment	Primary end point	Results
Masuda et al., 1992⁶⁵	31	Stage I, II or III	VNBL+DOXO+UFT	OS	Improvement in the 5-year OS
Atzpodien et al., 2005⁶⁶	203	pT3b/c–abb, N1–3, resected M1	IL-2+IFN-α-2a+5-FU	OS	Detrimental in OS
Aitchison et al., 2011⁶⁷	309	High risk patients	IL-2+IFN-α+ and 5-fluorouracil	DFS	No difference in OS No difference in DFS

IL-2, interleukin-2; IFN-α, interpheron-α; 5-FU, 5-fluorouracil; VNBL, vinblastine; DOXO, doxorubicin; UFT, tegafur-uracil; OS, overall survival; DFS, disease free survival.